Multi-omics Study of Early-stage Lung Cancer with Distinct Phenotypes

Cohort 1: Multi-omics study in early-stage synchronous multiple primary lung cancer

Inclusion criteria:

1. Male or female patients:18-75 years old;

2. ECOG score:0-1;

3. Histopathologically confirmed TNM stage I-II NSCLC;

4. Considered multiple or solitary primary lung cancer by clinical criteria (Martini-Melamed criteria and ACCP criteria);

5. Good compliance, family members agree to cooperate to receive survival follow-up;

6. Understand and voluntarily sign the informed consent.

Exclusion criteria:

1. A history of previous or co-existing malignant tumors;

2. Systemic anti-tumor therapies, including chemotherapy, radiotherapy, or targetedtherapies (such as monoclonal antibodies, small-molecule tyrosine kinase inhibitors,among others), were administered prior to enrollment;

3. Refusal to participate in the study.

Cohort 2: Multi-omics study of lung cancer associated with cystic airspaces

Inclusion criteria:

1. Male or female patients:18-75 years old;

2. ECOG score:0-1;

3. Histopathologically confirmed TNM stage I-II NSCLC;

4. CT findings show solitary or multiple nodules with cystic airspaces.

Exclusion criteria:

1. A history of previous or co-existing malignant tumors;

2. Systemic anti-tumor therapies, including chemotherapy, radiotherapy, or targetedtherapies (such as monoclonal antibodies, small-molecule tyrosine kinase inhibitors,among others), were administered prior to enrollment;

3. Refusal to participate in the study.